These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18786981)

  • 41. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
    BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
    Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
    Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
    Helbekkmo N; Sundstrøm SH; Aasebø U; Brunsvig PF; von Plessen C; Hjelde HH; Garpestad OK; Bailey A; Bremnes RM;
    Br J Cancer; 2007 Aug; 97(3):283-9. PubMed ID: 17595658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
    Wang Z; Huang C; Yang JJ; Song Y; Cheng Y; Chen GY; Yan HH; Ben XS; Wang BC; Xu CR; Jiang BY; Zhou Q; Chen HJ; Wu YL
    Eur J Cancer; 2019 Mar; 109():183-191. PubMed ID: 30739019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
    J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
    Westeel V; Quoix E; Puyraveau M; Lavolé A; Braun D; Laporte S; Bigay-Game L; Pujol JL; Ozenne G; Rivière A; Douillard JY; Lebeau B; Debieuvre D; Poudenx M; David P; Molinier O; Zalcman G; Lemarié E; Morin F; Depierre A; Milleron B;
    Eur J Cancer; 2013 Aug; 49(12):2654-64. PubMed ID: 23735703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
    Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
    Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Yamamoto N; Nishio M; Ohe Y; Kato T; Takahashi T; Kamada A; Suzukawa K; Omori Y; Enatsu S; Nakagawa K; Tamura T
    Lung Cancer; 2019 Mar; 129():55-62. PubMed ID: 30797492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.